JP2022525545A5 - - Google Patents
Info
- Publication number
- JP2022525545A5 JP2022525545A5 JP2021556508A JP2021556508A JP2022525545A5 JP 2022525545 A5 JP2022525545 A5 JP 2022525545A5 JP 2021556508 A JP2021556508 A JP 2021556508A JP 2021556508 A JP2021556508 A JP 2021556508A JP 2022525545 A5 JP2022525545 A5 JP 2022525545A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- complement
- nucleotide sequence
- srebf1
- position corresponding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962820893P | 2019-03-20 | 2019-03-20 | |
| US62/820,893 | 2019-03-20 | ||
| US201962879138P | 2019-07-26 | 2019-07-26 | |
| US62/879,138 | 2019-07-26 | ||
| PCT/US2020/023532 WO2020191141A1 (en) | 2019-03-20 | 2020-03-19 | Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (srebf1) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022525545A JP2022525545A (ja) | 2022-05-17 |
| JP2022525545A5 true JP2022525545A5 (enExample) | 2023-03-22 |
| JP7574206B2 JP7574206B2 (ja) | 2024-10-28 |
Family
ID=70289471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556508A Active JP7574206B2 (ja) | 2019-03-20 | 2020-03-19 | ステロール調節エレメント結合転写因子１（ｓｒｅｂｆ１）阻害剤による上昇した脂質レベルの治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11504390B2 (enExample) |
| EP (1) | EP3942048A1 (enExample) |
| JP (1) | JP7574206B2 (enExample) |
| CN (2) | CN113727732B (enExample) |
| CA (1) | CA3133000A1 (enExample) |
| WO (1) | WO2020191141A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3201466A1 (en) | 2020-12-14 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors |
| CN116583291A (zh) * | 2020-12-14 | 2023-08-11 | 雷杰纳荣制药公司 | 用抑制素亚基βE(INHBE)抑制剂治疗代谢病症和心血管疾病的方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5688787A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
| EP0633875B1 (en) | 1992-04-03 | 1997-01-02 | Gist-Brocades N.V. | Selective n-acylation of amino alcohols |
| LT3595B (en) | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| FR2710337B1 (fr) | 1993-09-23 | 1995-12-08 | Gerard Coquerel | Procédé de dédoublement de deux antipodes optiques par entraînement polythermique programmé et autoensemencé. |
| US5624920A (en) | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5633246A (en) | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5656624A (en) | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
| US5756470A (en) | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6602710B1 (en) | 1998-08-27 | 2003-08-05 | Chugai Seiyaku Kabushiki Kaisha | Screening method for SREBP pathway-specific inhibitors |
| GB9916757D0 (en) | 1999-07-17 | 1999-09-15 | Glaxo Group Ltd | Method |
| EP1345895B1 (de) | 2000-12-21 | 2006-12-27 | Sanofi-Aventis Deutschland GmbH | Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen |
| TWI291957B (en) | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
| US20080249040A1 (en) | 2001-05-18 | 2008-10-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of sterol regulatory element binding protein 1 (SREBP1) gene expression using short interfering nucleic acid (siNA) |
| AU2002320621A1 (en) | 2001-07-20 | 2003-03-03 | Incyte Genomics, Inc. | Structural and cytoskeleton-associated proteins |
| WO2003033656A2 (en) * | 2001-10-16 | 2003-04-24 | Exelixis, Inc. | MSREBPs AS MODIFIERS OF THE SREBP PATHWAY AND METHODS OF USE |
| US20050014177A1 (en) | 2003-05-19 | 2005-01-20 | Koustubh Ranade | Human sterol response element binding protein 1 (SREBP1) single nucleotide polymorphisms |
| CA2658183A1 (en) * | 2006-07-17 | 2008-01-24 | Sirna Therapeutics Inc. | Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina) |
| AU2007297388A1 (en) | 2006-09-18 | 2008-03-27 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of scap and therapeutic uses thereof |
| JP2010053122A (ja) * | 2008-07-31 | 2010-03-11 | Hayashibara Biochem Lab Inc | 脂質合成阻害剤 |
| US9187746B2 (en) | 2009-09-22 | 2015-11-17 | Alnylam Pharmaceuticals, Inc. | Dual targeting siRNA agents |
| EP2515901A2 (en) * | 2009-12-22 | 2012-10-31 | The Administrators of the Tulane Educational Fund | Compositions and methods for treating obesity and diabetes |
| WO2015100257A1 (en) | 2013-12-23 | 2015-07-02 | The General Hospital Corporation | Methods and assays for determining reduced brca1 pathway function in a cancer cell |
| EP3387129A1 (en) | 2015-12-10 | 2018-10-17 | Alnylam Pharmaceuticals, Inc. | STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| CN105441454B (zh) | 2015-12-23 | 2018-12-11 | 北京大学人民医院 | Scap基因突变体及其应用 |
| WO2017191165A1 (en) | 2016-05-03 | 2017-11-09 | Lonza Ltd | Modulation of lipid metabolism for protein production |
| CN111655851A (zh) * | 2018-01-18 | 2020-09-11 | 哥本哈根罗氏创新中心 | 靶向srebp1的反义寡核苷酸 |
| EP3746070A4 (en) | 2018-01-29 | 2021-09-01 | Capulus Therapeutics, LLC | SREBP INHIBITORS WITH A 6-LINKED CENTER RING |
| US11648260B2 (en) | 2018-03-29 | 2023-05-16 | Technion Research And Development Foundation Limitted | Vesicles comprising a PTEN inhibitor and uses of same |
| CN109536610B (zh) * | 2018-12-05 | 2020-10-16 | 西南大学 | Setdb1在调控胆固醇途径中的应用 |
-
2020
- 2020-03-19 EP EP20719278.2A patent/EP3942048A1/en active Pending
- 2020-03-19 CA CA3133000A patent/CA3133000A1/en active Pending
- 2020-03-19 CN CN202080030927.3A patent/CN113727732B/zh active Active
- 2020-03-19 CN CN202310867404.XA patent/CN116889627A/zh active Pending
- 2020-03-19 US US16/823,634 patent/US11504390B2/en active Active
- 2020-03-19 WO PCT/US2020/023532 patent/WO2020191141A1/en not_active Ceased
- 2020-03-19 JP JP2021556508A patent/JP7574206B2/ja active Active
-
2022
- 2022-10-17 US US18/047,026 patent/US20230263821A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007139811A1 (en) | Methods and kits for linking polymorphic sequences to expanded repeat mutations | |
| JP2022523301A5 (enExample) | ||
| WO2008147930A2 (en) | Methods and kits for linking polymorphic sequences to expanded repeat mutations | |
| WO2008064519A1 (en) | Methods and compositions for diagnosis of esophageal cancer and prognosis and improvement of patient survival | |
| JP2023531935A5 (enExample) | ||
| JP2022525545A5 (enExample) | ||
| US9765398B2 (en) | Exonic splicing enhancers and exonic splicing silencers | |
| JP7574206B2 (ja) | ステロール調節エレメント結合転写因子１（ｓｒｅｂｆ１）阻害剤による上昇した脂質レベルの治療 | |
| JP2022525546A5 (enExample) | ||
| JP4842256B2 (ja) | 遺伝子一塩基多型解析によるアトピー性皮膚炎の相対罹患危険率の検出方法 | |
| US20080050358A1 (en) | Identification of Snps Associated with Hyperlipidemia, Dyslipidemia and Defective Carbohydrate Metabolism | |
| JP2024521224A (ja) | 神経原性座位Ｎｏｔｃｈホモログタンパク質３（ＮＯＴＣＨ３）剤による脳血管疾患の治療 | |
| JP2022515838A5 (enExample) | ||
| EP4363585A1 (en) | Methods of treating decreased bone mineral density with kringle containing transmembrane protein 1 (kremen1) inhibitors | |
| JP2024522148A (ja) | インターフェロン誘導ヘリカーゼｃドメイン１（ｉｆｉｈ１）阻害剤による乾癬の治療 | |
| JP2022525456A5 (enExample) | ||
| Tjärnlund-Wolf et al. | Allelic imbalance of tissue-type plasminogen activator (t-PA) gene expression in human brain tissue | |
| AU2022356375B2 (en) | Reticulocalbin-3 (rcn3) variants and treatment of asthma with interleukin-4 receptor alpha (il4r) antagonists | |
| CN117795075A (zh) | 使用溶质载剂家族27成员3(slc27a3)抑制剂治疗哮喘的方法 | |
| JP2024524374A (ja) | 溶質輸送体ファミリー９アイソフォームａ３調節因子２（ｓｌｃ９ａ３ｒ２）阻害剤による高血圧症の治療 | |
| CN121175436A (zh) | 用压电式机械敏感离子通道组分1(piezo1)激动剂治疗静脉曲张 | |
| EP4466357A2 (en) | Methods of improving health with apolipoprotein e (apoe) inhibitors | |
| AU2022300980A1 (en) | Treatment of cognitive impairment with alpha-n-acetylgalactosaminide alpha-2,6-sialyltransferase 5 (st6galnac5) inhibitors | |
| CN118804976A (zh) | 用整联蛋白亚基α1(ITGA1)抑制剂治疗肺部疾患 | |
| JP2024508824A5 (enExample) |